Azbil BioVigilant announces decision to deploy IMD-A rapid microbial monitoring system by compounding pharmacy innovator
8 October 2012 | By Azbil BioVigilant
Leiter Rx will utilize Azbil BioVigilant’s IMD-A® 300-series systems...
List view / Grid view
8 October 2012 | By Azbil BioVigilant
Leiter Rx will utilize Azbil BioVigilant’s IMD-A® 300-series systems...
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
8 October 2012 | By Teva Pharmaceutical Industries Ltd
Key data from the Company’s MS franchise...
5 October 2012 | By Sanofi
New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...
5 October 2012 | By Novo Nordisk
4/5 people with type 2 diabetes have experienced self-treated hypoglycaemia...
4 October 2012 | By Boehringer Ingelheim
New data from HCVersoTM have been accepted for presentation...
4 October 2012 | By GlaxoSmithKline
Dolutegravir is not yet approved as a treatment for HIV...
4 October 2012 | By Pfizer
Pfizer has announced top-line data...
3 October 2012 | By Merck
Phase III trials of MK-3102 underway...
3 October 2012 | By Novo Nordisk
"We know from clinical practice that liraglutide is highly effective..."
3 October 2012 | By Bristol-Myers Squibb Company
Sanofi & Bristol-Myers Squibb have restructured their long-term alliance...
2 October 2012 | By kdm communications limited
TECAN and JPT Peptide Technologies GmbH announced a collaborative agreement between the two specialist companies...
2 October 2012 | By Novo Nordisk
Than insulin glargine in a 2-year study investigating people with type 2 diabetes...
2 October 2012 | By Boehringer Ingelheim
Patient-reported health outcomes data from a Phase II study...